BerandaABVX • NASDAQ
add
Abivax SA
Tutup sebelumnya
$69,09
Rentang hari
$69,07 - $71,42
Rentang tahun
$4,77 - $75,51
Kapitalisasi pasar
4,56Â M EUR
Volume Rata-Rata
2,26Â jt
Rasio P/E
-
Hasil dividen
-
Berita pasar
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
| (EUR) | Mar 2025info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 970,00Â rb | -17,38% |
Biaya operasional | 48,17Â jt | 5,07% |
Laba bersih | -52,37Â jt | -22,17% |
Margin laba bersih | -5,40Â rb | -47,86% |
Penghasilan per saham | — | — |
EBITDA | -47,12Â jt | -5,63% |
Tarif pajak efektif | — | — |
Neraca
Total aset
Total liabilitas
| (EUR) | Mar 2025info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 103,58Â jt | -60,34% |
Total aset | 166,94 jt | — |
Total liabilitas | 173,53 jt | — |
Total ekuitas | -6,59 jt | — |
Saham yang beredar | 63,42 jt | — |
Harga terhadap nilai buku | -690,90 | — |
Tingkat pengembalian aset | -63,41% | — |
Tingkat pengembalian modal | -94,49% | — |
Arus Kas
Perubahan kas bersih
| (EUR) | Mar 2025info | Perubahan Y/Y |
|---|---|---|
Laba bersih | -52,37Â jt | -22,17% |
Kas dari operasi | -33,28Â jt | 4,25% |
Kas dari investasi | 1,08Â jt | -43,08% |
Kas dari pembiayaan | -7,84Â jt | -136,97% |
Perubahan kas bersih | -40,64Â jt | -293,31% |
Arus kas bebas | -19,05 jt | — |
Tentang
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has one program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, MA. Abivax’s R&D work is conducted at its research center based in Montpellier, France. Wikipedia
Didirikan
4 Des 2013
Situs
Karyawan
69
